GLP-1 Meds Linked to Symptomatic Remission in UC

TOPLINE Among patients with ulcerative colitis (UC), GLP-1 receptor agonist (RA) therapy was associated with substantially higher symptomatic remission rates at 12 weeks than no GLP-1 RA therapy, with benefits appearing independent of weight loss; remission rates were higher with semaglutide than liraglutide. METHODOLOGY Although previous studies linked GLP-1 RA use to favorable inflammatory bowel …